Comparative effectiveness of bivalent BA.4–5 or BA.1 mRNA booster vaccines among immunocompromised individuals across three Nordic countries: A nationwide cohort study - 17/09/24
, Emilia Myrup Thiesson a, Nicklas Pihlström b, Jori Perälä c, Eero Poukka c, d, Tuija Leino c, Rickard Ljung e, f, Niklas Worm Andersson a, Anders Hviid a, gSummary |
Objectives |
To estimate the effectiveness and waning of the bivalent BA.4–5 or BA.1 mRNA booster vaccine against Covid-19-related hospitalization and death in immunocompromised individuals.
Methods |
Nationwide analyses across Nordic countries from 1 September 2022 to 31 October 2023 using a matched cohort design. Individuals boosted with a BA.4–5 or BA.1 vaccine were matched 1:1 with unboosted individuals. The outcomes of interest were country-combined vaccine effectiveness (VE) estimates against Covid-19-related hospitalization and death at day 270 of follow-up. Waning was assessed in 45-day intervals.
Results |
A total of 352,762 BA.4–5 and 191,070 BA.1 booster vaccine doses were included. At day 270, the comparative VE against Covid-19-related hospitalization was 34.2% (95% CI, 7.1% to 61.3%) for the bivalent BA.4–5 vaccine and 42.6% (95% CI, 31.3% to 53.9%) for the BA.1 vaccine compared with matched unboosted. The comparative VE against Covid-19-related death was 53.9% (95% CI, 38.6% to 69.3%) for the bivalent BA.4–5 vaccine and 57.9% (95% CI, 48.5% to 67.4%) for the BA.1 vaccine.
Conclusions |
In immunocompromised individuals, vaccination with bivalent BA.4–5 or BA.1 booster lowered the risk of Covid-19-related hospitalization and death over a follow-up period of 9 months. The effectiveness was highest during the first months since vaccination with subsequent gradual waning.
Le texte complet de cet article est disponible en PDF.Keywords : Vaccine effectiveness, Covid-19, Immunocompromised
Plan
Vol 89 - N° 4
Article 106261- octobre 2024 Retour au numéro
Article précédent
- BCG vaccination of healthcare workers for protection against COVID-19: 12-month outcomes from an international randomised controlled trial
- Nicole L. Messina, Laure F. Pittet, Ellie McDonald, Cecilia Moore, Simone Barry, Marc Bonten, Anthony Byrne, John Campbell, Julio Croda, Mariana G. Croda, Margareth Dalcolmo, Fernando F. de Almeida e Val, Roberto D. de Oliveira, Glauce dos Santos, Mark W. Douglas, Kaya Gardiner, Amanda Gwee, Bruno A. Jardim, Tobias Kollmann, Marcus VG Lacerda, Michaela Lucas, David J. Lynn, Laurens Manning, Helen Marshall, Abby O’Connell, Kirsten P. Perrett, Jeffrey J. Post, Cristina Prat-Aymerich, Jorge L. Rocha, Jesus Rodriguez-Baño, Ushma Wadia, Adilia Warris, Andrew Davidson, Nigel Curtis, the BRACE Trial Consortium Group
- The IL-6 hypothesis in COVID-19: A phase 2, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of free IL-6 sequestration by the monoclonal antibody sirukumab in severe and critical COVID-19
- Robert L. Gottlieb, Meredith Clement, Paul Cook, Audra Deveikis, Kap Sum Foong, Philip Robinson, Jihad Slim, Cedric W. Spak, Annemie Buelens, Katleen Callewaert, Sandra De Meyer, Wai Ling Mo, Inge Verbrugge, Liesbeth Van Wesenbeeck, Yanli Zhuang, Jason W. Chien, Magda Opsomer, Erika Van Landuyt
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?